Previously documented adverse cardiovascular side effects of VEGF inhibition include hypertension, thought due to inhibition of nitric oxide production, leading to endothelial dysfunction and vasoconstriction [27] and arterial thromboembolism via an increase in endothelial cell apoptosis, with disruption of the endothelial lining and subsequent exposure to underlying pro-coagulant factors [28] [20]. The gene discussed is VEGFA; the disease is endothelial dysfunction.